X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs GLENMARK PHARMA - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD GLENMARK PHARMA BIOCON LTD/
GLENMARK PHARMA
 
P/E (TTM) x 50.6 19.8 256.0% View Chart
P/BV x 7.4 3.5 213.2% View Chart
Dividend Yield % 0.2 0.3 51.7%  

Financials

 BIOCON LTD   GLENMARK PHARMA
EQUITY SHARE DATA
    BIOCON LTD
Mar-18
GLENMARK PHARMA
Mar-18
BIOCON LTD/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,188930 127.7%   
Low Rs305517 58.9%   
Sales per share (Unadj.) Rs68.7322.6 21.3%  
Earnings per share (Unadj.) Rs7.628.5 26.5%  
Cash flow per share (Unadj.) Rs14.039.2 35.6%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %0.10.3 48.5%  
Book value per share (Unadj.) Rs86.3183.0 47.2%  
Shares outstanding (eoy) m600.00282.17 212.6%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.92.2 484.2%   
Avg P/E ratio x98.925.4 389.1%  
P/CF ratio (eoy) x53.418.5 289.3%  
Price / Book Value ratio x8.64.0 218.6%  
Dividend payout %13.27.0 188.6%   
Avg Mkt Cap Rs m447,900204,206 219.3%   
No. of employees `0006.113.7 44.8%   
Total wages/salary Rs m9,31118,718 49.7%   
Avg. sales/employee Rs Th6,705.86,636.8 101.0%   
Avg. wages/employee Rs Th1,514.21,364.7 111.0%   
Avg. net profit/employee Rs Th736.9586.1 125.7%   
INCOME DATA
Net Sales Rs m41,23491,031 45.3%  
Other income Rs m2,062914 225.6%   
Total revenues Rs m43,29691,945 47.1%   
Gross profit Rs m8,29116,154 51.3%  
Depreciation Rs m3,8513,019 127.6%   
Interest Rs m6152,856 21.5%   
Profit before tax Rs m5,88711,193 52.6%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5693,155 49.7%   
Profit after tax Rs m4,5318,039 56.4%  
Gross profit margin %20.117.7 113.3%  
Effective tax rate %26.728.2 94.6%   
Net profit margin %11.08.8 124.4%  
BALANCE SHEET DATA
Current assets Rs m41,48669,887 59.4%   
Current liabilities Rs m21,41332,879 65.1%   
Net working cap to sales %48.740.7 119.7%  
Current ratio x1.92.1 91.1%  
Inventory Days Days6481 78.6%  
Debtors Days Days9493 100.7%  
Net fixed assets Rs m50,66128,892 175.3%   
Share capital Rs m3,000282 1,063.1%   
"Free" reserves Rs m48,80851,353 95.0%   
Net worth Rs m51,80851,635 100.3%   
Long term debt Rs m17,89841,418 43.2%   
Total assets Rs m99,897125,954 79.3%  
Interest coverage x10.64.9 214.9%   
Debt to equity ratio x0.30.8 43.1%  
Sales to assets ratio x0.40.7 57.1%   
Return on assets %5.28.6 59.6%  
Return on equity %8.715.6 56.2%  
Return on capital %9.615.1 63.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,05836,317 33.2%   
Fx outflow Rs m7,3489,720 75.6%   
Net fx Rs m4,71026,598 17.7%   
CASH FLOW
From Operations Rs m6,62116,481 40.2%  
From Investments Rs m-6,840-10,133 67.5%  
From Financial Activity Rs m-2,397-4,685 51.2%  
Net Cashflow Rs m-2,6121,770 -147.6%  

Share Holding

Indian Promoters % 40.4 48.3 83.6%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 6.9 121.7%  
FIIs % 10.7 34.4 31.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 10.5 189.5%  
Shareholders   109,995 56,727 193.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   STERLING BIOTECH  PFIZER  ALKEM LABORATORIES  ORCHID PHARMA LTD  SANOFI INDIA  

Compare BIOCON LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 629 Points Higher; Realty and Auto Stocks Witness Buying(Closing)

Indian share markets continued their momentum throughout the day and ended the day on a strong note. Gains were largely seen in the realty sector, telecom sector and auto sector.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Dec 12, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD 8-QTR ANALYSIS

COMPARE BIOCON LTD WITH

MARKET STATS